Loading clinical trials...
Loading clinical trials...
Study of PD-1 Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma
Conditions
Interventions
Toripalimab and Anlotinib
Locations
1
China
Qilu Hospital of Shandong University
Jinan, Shandong, China
Start Date
November 1, 2021
Primary Completion Date
September 30, 2023
Completion Date
October 30, 2023
Last Updated
October 21, 2021
Lead Sponsor
Qilu Hospital of Shandong University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions